Cargando…

Correction: Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience

Detalles Bibliográficos
Autores principales:	Jablonska, Paola Anna, Diez-Valle, Ricardo, Gállego Pérez-Larraya, Jaime, Moreno-Jiménez, Marta, Idoate, Miguel Ángel, Arbea, Leire, Tejada, Sonia, de Eulate, Maria Reyes Garcia, Ramos, Luis, Arbizu, Javier, Domínguez, Pablo, Aristu, José Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613680/ https://www.ncbi.nlm.nih.gov/pubmed/31283793 http://dx.doi.org/10.1371/journal.pone.0219614

Ejemplares similares

Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience
por: Jablonska, Paola Anna, et al.
Publicado: (2019)

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
por: Inogés, Susana, et al.
Publicado: (2017)

Erratum to: Factors associated with a higher rate of distant failure after primary treatment for glioblastoma
por: Tejada, Sonia, et al.
Publicado: (2013)

Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications
por: Arbea, Leire, et al.
Publicado: (2010)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Factors associated with a higher rate of distant failure after primary treatment for glioblastoma
por: Tejada, Sonia, et al.
Publicado: (2013)

Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature
por: Chidley, Phoebe, et al.
Publicado: (2022)

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
por: Jastaniyah, Noha, et al.
Publicado: (2013)

Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
por: Rodríguez-Ruiz, María Esperanza, et al.
Publicado: (2012)

Pneumomediastinum as a complication of SABR for lung metastases
por: Rodríguez-Ruiz, María Esperanza, et al.
Publicado: (2015)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
por: Zhong, Liangzhi, et al.
Publicado: (2019)

(18)F-FDG-PET Imaging Patterns in Autoimmune Encephalitis: Impact of Image Analysis on the Results
por: Moreno-Ajona, David, et al.
Publicado: (2020)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
por: Yi, Fuxin, et al.
Publicado: (2017)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
por: Damato, Anna R, et al.
Publicado: (2021)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Technical flaws in multiple-choice questions in the access exam to medical specialties (“examen MIR”) in Spain (2009–2013)
por: Rodríguez-Díez, María Cristina, et al.
Publicado: (2016)

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma
por: Lee, I-Neng, et al.
Publicado: (2021)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report
por: Martin-Romano, P., et al.
Publicado: (2017)

Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
por: Jablonska, Paola Anna, et al.
Publicado: (2021)

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_umtvsrt7rg0d4qu11cbes1ujd4